Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Tumors that express wild-type P53 provide a target for therapies designed to reactivate P53 function. This is supported by the potent activation of P53 in tumor cells by Nutlin, a cis-imidazoline that inhibits the Hdm2-P53 interaction. The efficacy of Hdm2.P53 antagonists could be compromised if they do not antagonize Hdmx, an Hdm2 homolog that inhibits P53 transactivation. We evaluated the role of Hdmx expression in sensitivity to Nutlin in a range of cancer cell lines. Nutlin reduced Hdmx levels in normal cells and some cancer cell lines, whereas other cancer cells were refractory to such down-regulation. Strikingly, Nutlin did not disrupt Hdmx.P53 complexes, and in cell lines where no Hdmx degradation occurred, Nutlin failed to induce apoptosis. shRNA-mediated reduction of Hdmx sensitized cells to apoptosis, but caspase-3 was neither required nor sufficient for Hdmx degradation or apoptosis. Our data imply that Hdmx is an important determinant of the outcome of P53 activation. Thus, targeting Hdmx may be a therapeutic strategy that complements drugs such as Nutlin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [30]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [102]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis
Jänicke, R. U., Sprengart, M. L., Wati, M. R., & Porter, A. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9357 · Cited by 1,953
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Research works printed but not linked: 3
- Schwartzberg, 2006, J. Support. Oncol., 42, 3
- Finch, 2002, Cancer Res., 62, 3221
- Tian, 2006, Biochem. Biophys. Res. Commun., 2, 2
Cited by
Items 101–166 of 166
Giustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25
N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53
Hayashi, R., Wang, D., Hara, T. J., Iera, J. A., Durell, S. R., & Appella, D. H. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.032 · Cited by 25
Moawad, M., Nasr, G. M., Osman, A. S., & Shaker, E. S. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231176396 · Cited by 22
Heminger, K., Markey, M. P., Mpagi, M. D., & Berberich, S. J. (2009) · Aging · doi:10.18632/aging.100008 · Cited by 25
Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 20
Tsuganezawa, K., Nakagawa, Y., Kato, M., Taruya, S., Takahashi, F., Endoh, M., Utata, R., Mori, M., Ogawa, N., Honma, T., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112460729 · Cited by 21
SRSF2 Regulation of MDM2 Reveals Splicing as a Therapeutic Vulnerability of the p53 Pathway
Comiskey, D. F., Montes, M., Khurshid, S., Singh, R. K., & Chandler, D. S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0541 · Cited by 19
Han, X., Medeiros, L. J., Zhang, Y. H., You, M. J., Andreeff, M., Konopleva, M. Y., & Bueso-Ramos, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.03.012 · Cited by 20
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 19
Ji, K., Wang, B., Shao, Y., Zhang, L., Liu, Y., Shao, C., Li, X., Li, X., Hu, J., Zhao, X., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180364 · Cited by 19
Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16
Bohio, A. A., Wang, R., Zeng, X., & Ba, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11156 · Cited by 15
GENG, Q.-Q., DONG, D.-F., CHEN, N.-Z., WU, Y.-Y., Li, E. X., Wang, J., & Wang, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2138 · Cited by 18
Joshi, M. R., Yao, N., Myers, K. A., & Li, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080926 · Cited by 15
Imidazoline derivatives: a patent review (2006 – present)
Guan, X., & Hu, Y. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.727397 · Cited by 19
Hirose, M., Yamato, K., Endo, S., Saito, R., Ueno, T., Hirai, S., Suzuki, H., Abei, M., Natori, Y., & Hyodo, I. (2014) · Oncoscience · doi:10.18632/oncoscience.103 · Cited by 16
Carotti, A., Macchiarulo, A., Giacchè, N., & Pellicciari, R. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22464 · Cited by 14
Liu, X., Rossio, V., Gygi, S. P., & Paulo, J. A. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00806 · Cited by 15
Mdm2 and MdmX Involvement in Human Cancer
Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12
Structure of Human MDM4 N-Terminal Domain Bound to a Single-Domain Antibody
Yu, G. W., Vaysburd, M., Allen, M. D., Settanni, G., & Fersht, A. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.043 · Cited by 14
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population
Reza, H. A., Anamika, W. J., Chowdhury, M. M. K., Mostafa, M., & Uddin, M. A. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.125 · Cited by 11
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99
Lee, X. A., Verma, C. S., & Sim, A. Y. L. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25310 · Cited by 9
Mitobe, Y., Suzuki, S., Nakagawa-Saito, Y., Togashi, K., Sugai, A., Sonoda, Y., Kitanaka, C., & Okada, M. (2023) · Cancers · doi:10.3390/cancers15174326 · Cited by 9
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system
Datta, S., Bucks, M. E., Koley, D., Lim, P. X., & Savinov, S. N. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.053 · Cited by 11
Jones, T., Sigauke, R. F., Sanford, L., Taatjes, D. J., Allen, M. A., & Dowell, R. D. (2025) · Genome biology · doi:10.1186/s13059-025-03545-2 · Cited by 8
TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin‐3a‐Induced Cell Death
Lee, J., An, S., Choi, Y. M., Jung, J. H., Li, L., Meng, H., Dong, Y., Ahn, K. J., An, I., & Bae, S. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25831 · Cited by 7
FAM193A is a positive regulator of p53 activity
Szwarc, M. M., Guarnieri, A. L., Joshi, M., Duc, H. N., Laird, M. C., Pandey, A., Khanal, S., Dohm, E., Bui, A. K., Sullivan, K. D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112230 · Cited by 8
Kong, Q., Li, P., Tian, Q., & Min-wen, H. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0506 · Cited by 8
Ceol, A. G. M., Verhoef, L. G. G. C., Wade, M. R., & Müller, H. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0908-x · Cited by 5
Self-citationNguyen, K. V. (2022) · AIMS neuroscience · doi:10.3934/neuroscience.2022010 · Cited by 5
Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression
Cao, L., Hu, Y., Jia, K., Ruiz-Cardozo, M. A., Chen, E., Yang, J., Shao, Z., Tine, B. A. V., & Wu, W. (2025) · Research · doi:10.34133/research.0977 · Cited by 5
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Pujals, A., Favre, L., Gaulard, P., & Wiels, J. (2015) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s60486 · Cited by 5
Antineoplastic activity of idazoxan hydrochloride
Eilon, G., Weisenthal, L. M., Stupecky, M., Landucci, G., & Slater, L. M. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0978-9 · Cited by 4
Banerjee, A., & Ray, S. (2016) · Scientifica · doi:10.1155/2016/9420692 · Cited by 4
Malignant transformation of oral lichen planus and related genetic factors
Hwang, E. C., Choi, S., & Kim, J. H. (2020) · International Journal of Oral Biology · doi:10.11620/ijob.2020.45.1.1 · Cited by 3
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2
Ming-xing, H., Song, Y., Gao, P., Li, H., & Liu, W. (2023) · SN Applied Sciences · doi:10.1007/s42452-023-05584-5 · Cited by 2
Ntwasa, M. M. (2024) · Cells · doi:10.3390/cells13131124 · Cited by 2
Cooperation between MDM2 and MDMX in the Regulation of p53
Blaydes, J. P. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_6 · Cited by 3
Forte, E., & Luftig, M. (2009) · Infectious Agents and Cancer · doi:10.1186/1750-9378-4-s2-p26 · Cited by 2
Pisamai, S., Edwards, S. W., Cheng, C. W., Chaivichit, P., Sooksiri, M., Yanakam, S., Maneewong, S., & Suriyaphol, G. (2023) · Research in Veterinary Science · doi:10.1016/j.rvsc.2023.105036 · Cited by 2
Targeting p53 Tumor Suppressor for AML Therapy
Kojima, K., & Vassilev, L. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_7 · Cited by 1
Targeting p53-MDM2 Interaction by Natural Plant Products: A Novel Approach for Future Cancer Therapy
Rao, M. V. R., Raj, B., Acharya, Y., Nayak, S. J. K., Sireeshabala, A., & Pawar, A. C. (2017) · SSR Institute of International Journal of Life Sciences · doi:10.21276/ijlssr.2017.3.2.12 · Cited by 1
The role of TRIM39 in cell cycle and apoptosis
Huang, N.-J. (2013) · DukeSpace (Duke University)
Molecular mechanisms of growth suppression by pharmacologically activated p53
Hedström, E. (2009) · Figshare
Sarek, G. (2010) · Helda - University of Helsinki Institutional Repository
Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction
Shangary, S. K., Bernard, D., & Wang, S. (2010) · Wiley eBooks · doi:10.1002/9780470972137.ch10
Characterization of the Ubiquitin/Nedd8 E3 ligase activity of the Mdm2/MdmX complex
Singh, R. K. (2007) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Cellular Changes and Effects of Cytokines in the Transformation of Human Mammary Epithelial Cells
Kan, C. E. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Impact of MDM2 309T>G polymorphism on sarcomagenesis.
Liu, H.-W., Ni, M., Li, X., Chen, H., Zhang, G., Chai, W., Xu, M., Zhou, Y.-G., Chen, J., & Wang, Y. (2015) · Europe PMC (PubMed Central)
Hit-to-lead optimization of pharmaceutical interesting tryptophanol-derived scaffolds
Barcherini, V. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Veerakumarasivam, A., Scott, H. E., Chin, S., Warren, A. Y., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., et al. (2023) · doi:10.1158/1078-0432.c.6516990
Data from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2023) · doi:10.1158/1535-7163.c.6531407
Veerakumarasivam, A., Scott, H. E., Chin, S., Warren, A. Y., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., et al. (2023) · doi:10.1158/1078-0432.c.6516990.v1
Chen, W., Yang, K., Zhang, Y.-Z., Lin, Z.-S., Chen, J.-W., Qi, S.-F., Wu, C.-F., Feng, G.-K., Yang, D.-J., Chen, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26944368
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Durand, R. (2020) · theses.fr (ABES) · doi:10.70675/6ccc120bz65f7z4c6czabf5z9bea26651b66
BindingDB Entry 3460: N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
BindingDB (2009) · UC San Diego · doi:10.7270/q2057d90
Modulation of apoptosis and signalling in cancer cells after treatment with epigenetic modulators
Palani, R. N., & Devi, C. P. A. (2012) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Sarek, G., & Ojala, P. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1513-9_10
Metadata
- Authors
- Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Wahl, Geoffrey M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33036-33044
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2103069797
- Cited by
- 163
- References
- 57
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 11 · 2022: 1 · 2021: 2 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 8 · 2013: 13 · 2012: 13
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA61449, R01CA061449)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- HDMX, MDM2, p53 activation, nutlin, apoptosis, caspase-3, p53 transactivation, cancer cell lines, shRNA knockdown
- MeSH terms
- Humans, Imidazoles, Neoplasms, Nuclear Proteins, Piperazines, Protein Binding, Proto-Oncogene Proteins, Down-Regulation, Tumor Suppressor Protein p53, Apoptosis, Cell Cycle Proteins, RNA Interference, Cell Line, Tumor, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.